The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Zovirax IV for Infusion 250 mg, Powder for solution for infusion

250 milligram(s) Powder for solution for infusion

GlaxoSmithKline (Ireland) LimitedPA1077/084/003

Main Information

Trade NameZovirax IV for Infusion 250 mg, Powder for solution for infusion
Active SubstancesAciclovir
Strength250 milligram(s)
Dosage FormPowder for solution for infusion
Licence HolderGlaxoSmithKline (Ireland) Limited
Licence NumberPA1077/084/003

Group Information

ATC CodeJ05AB Nucleosides and nucleotides excl. reverse transcriptase inhibitors
J05AB01 aciclovir


Licence Issued03/05/1983
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back